#United States #Stamford #ZYN #Philip Morris International #smoke-free products

Philip Morris International's ZYN Portfolio Expansion

On September 9, 2026, PMI U.S., a branch of Philip Morris International (PMI), announced an exciting enhancement to its ZYN portfolio, aimed at adult nicotine consumers. This expansion is intended to provide a wider array of smoke-free options, tailored to individual preferences regarding nicotine strengths, flavors, and pouch formats.

The updated ZYN portfolio now features new additions to its flagship dry pouch lineup, introducing nicotine strengths of 1.5 mg and 8 mg, alongside the existing 3 mg and 6 mg options. Furthermore, PMI U.S. has unveiled the ZYN ULTRA, a moisture-rich oral nicotine pouch that offers customers an alternative that is completely free of tobacco leaf. This introduction reinforces the company's commitment to cater to diverse consumer needs, recognizing that tastes and preferences are not uniform across the board.

Stacey Kennedy, CEO of PMI U.S., remarked, "Forty-five million legal-age Americans use nicotine. PMI U.S. is dedicated to expanding our range of less harmful smoke-free products so that no adult ever smokes another cigarette because they can't find a suitable alternative." This statement underscores the company's aspiration to innovate and maintain consumer choice in its offerings.

The ZYN brand made headlines in January 2025 when it became the first nicotine pouch approved for sale in the U.S., validated by a thorough scientific review conducted by the U.S. Food and Drug Administration (FDA). Later, in June 2026, the FDA granted modified risk tobacco product orders for 20 ZYN varieties, allowing PMI U.S. to advertise that using ZYN instead of traditional cigarettes poses a lower risk of various health issues including mouth cancer and heart disease.

PMI U.S. continues to advance its offerings, transitioning its 3 mg and 6 mg dry pouch variants to a 20 pouch-per-can format based on research indicating consumer preference for that packaging size. The newly-introduced ZYN ULTRA products, which include ten 9 mg options and one 11 mg option, are backed by the FDA's marketing granted orders, ensuring that consumers can access science-backed choices.

ZYN's extensive lineup emphasizes several flavor profiles, including Cool Mint, Peppermint, Spearmint, and more, with ZYN ULTRA also introducing flavors like Arctic Mint and Fresh Spearmint.

These developments affirm PMI U.S.'s commitment to responsible marketing and ensuring products are accessible only to adults aged 21 and over. The company actively promotes measures to prevent underage access to its products. ZYN products are manufactured in the U.S., with large-scale production facilities present in Owensboro, Kentucky, and Aurora, Colorado, where a new campus began commercial operations in July 2026.

As PMI U.S. continues to innovate, they remain dedicated to providing quality smoke-free alternatives to the 25 million legal-age adults in the U.S. who use traditional cigarettes. With ongoing research and development, PMI U.S. aims to foster a smoke-free future for consumers who wish to transition away from combustible tobacco, reinforcing the message that consumer choice matters.

For more details, visit PMI's official website.